Drugs / Liposyn III
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00278928 | Jan 2006 → Apr 2007 | hypertriglyceridemia | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| — | NCT00002275 | — | HIV infectious disease | Abbott | Completed | No outcome recorded |
| — | NCT00002029 | — | HIV infectious disease | Abbott | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposyn III | “To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii...” NCT00002275 ↗2“Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent” NCT00002029 ↗ |
| Modality | Other / unclassified | “20% soybean oil-based lipid injectable emulsion” NCT00278928 ↗ |
| Route | Intravenous | “The decision to initiate intravenous nutritional support will be made by clinical personnel, and the dosing protocol for lipid injectable emulsion will follow institutional...” NCT00278928 ↗ |